Ichim Thomas E, Patel Amit N, Shafer Kim A
Institute for Molecular Medicine, Huntington Beach, CA, USA.
Department of Medicine, University of Utah, Salt Lake City, UT, USA.
J Transl Med. 2016 Jun 22;14(1):184. doi: 10.1186/s12967-016-0945-2.
Elevated levels of blood cholesterol are associated with cardiovascular disease, a leading cause of morbidity and mortality worldwide. Current therapies for addressing elevated blood cholesterol can be inadequate, ineffective or associated with side effects; therefore, the search for additional therapies is ongoing. This study evaluated Daily Body Restore (DBR), a proprietary blend of 9 probiotic organisms of the genera Lactobacillus and Bifidobacterium, and 10 digestive enzymes, for its effects on cholesterol metabolism using an in vitro system and a mouse model.
We used a murine model of hypercholesterolemia induced by a high fat diet to evaluate the effects of DBR on blood cholesterol concentrations. Hypercholesterolemic mice were supplemented with DBR in their drinking water for 8 weeks and compared to control mice given low fat diets or unsupplemented high fat diets. To evaluate the effects of DBR on the activity of gut microbiota in vitro, the Shime(®) system consisting of sequential colon reactors was supplemented with DBR for analysis of short chain fatty acid production.
Analysis of hypercholesterolemic mice after 4 and 8 weeks of DBR supplementation revealed significant decreases in blood concentrations of low-density lipoprotein (LDL) and increases in high-density lipoprotein (HDL) while triglyceride concentrations were unaltered. Specifically, after 4 weeks of DBR supplementation, there was a 47 % decrease in LDL and a 32 % increase in HDL in peripheral blood compared to unsupplemented, high fat diet-fed mice. After 8 weeks of DBR treatment, LDL concentrations were dramatically reduced by 78 % and HDL was increased by 52 % relative to control mice. Addition of DBR to the Shime(®) system led to significantly increased production of propionate in colon reactors, indicative of microbial production of short chain fatty acids known to inhibit cholesterol synthesis.
DBR, a probiotic and digestive enzyme supplement, lowered harmful LDL and increased HDL levels in a mouse model and also exerted in vitro effects consistent with cholesterol-lowering activity. Given the magnitude of the effects of DBR, these findings are promising for clinical implementation of DBR for treating hypercholesterolemia.
血液胆固醇水平升高与心血管疾病相关，心血管疾病是全球发病和死亡的主要原因。目前用于治疗血液胆固醇升高的疗法可能不充分、无效或伴有副作用；因此，人们一直在寻找其他疗法。本研究使用体外系统和小鼠模型评估了每日身体恢复剂（DBR），它是由9种乳酸杆菌属和双歧杆菌属益生菌以及10种消化酶组成的专利混合物，对胆固醇代谢的影响。
我们使用高脂肪饮食诱导的高胆固醇血症小鼠模型来评估DBR对血液胆固醇浓度的影响。给高胆固醇血症小鼠的饮用水中添加DBR，持续8周，并与给予低脂饮食或未添加DBR的高脂肪饮食的对照小鼠进行比较。为了在体外评估DBR对肠道微生物群活性的影响，由连续结肠反应器组成的希姆（Shime®）系统添加DBR以分析短链脂肪酸的产生。
对补充DBR 4周和8周后的高胆固醇血症小鼠进行分析发现，低密度脂蛋白（LDL）的血液浓度显著降低，高密度脂蛋白（HDL）增加，而甘油三酯浓度未改变。具体而言，与未补充DBR的高脂肪饮食喂养小鼠相比，补充DBR 4周后，外周血中LDL降低了47%，HDL增加了32%。DBR治疗8周后，相对于对照小鼠，LDL浓度显著降低了78%，HDL增加了52%。向希姆（Shime®）系统中添加DBR导致结肠反应器中丙酸的产生显著增加，这表明已知抑制胆固醇合成的短链脂肪酸的微生物产生。
DBR，一种益生菌和消化酶补充剂，在小鼠模型中降低了有害的LDL并提高了HDL水平，并且在体外也表现出与降胆固醇活性一致的作用。鉴于DBR的作用程度，这些发现对于DBR用于治疗高胆固醇血症的临床应用很有前景。
